Mereo BioPharma Group
Stock Forecast, Prediction & Price Target
Mereo BioPharma Group Financial Estimates
Mereo BioPharma Group Revenue Estimates
Mereo BioPharma Group EBITDA Estimates
Mereo BioPharma Group Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $36.46M N/A | $1.50M -95.86% | $10M 563.57% | Avg: $12.47M Low: $12.47M High: $12.47M avg. 24.76% | Avg: $17.53M Low: $17.53M High: $17.53M avg. 40.52% | Avg: $19.23M Low: $19.23M High: $19.23M avg. 9.69% | Avg: $81.58M Low: $81.58M High: $81.58M avg. 324.18% |
Net Income
% change YoY
| $12.72M N/A | $-34.19M -368.73% | $-29.46M 13.83% | Avg: $-25.80M Low: $-36.74M High: $-5.34M avg. 12.41% | Avg: $-51.48M Low: $-41.86M High: $-15.28M avg. -99.47% | Avg: $-46.78M Low: $-46.78M High: $-46.78M avg. 9.12% | Avg: $-20.79M Low: $-20.79M High: $-20.79M avg. 55.55% |
EBITDA
% change YoY
| $-20.31M N/A | $-42.06M -107.05% | $-26.05M 38.05% | Avg: $-6.38M Low: $-6.38M High: $-6.38M avg. 75.51% | Avg: $-8.96M Low: $-8.96M High: $-8.96M avg. -40.52% | Avg: $-9.83M Low: $-9.83M High: $-9.83M avg. -9.69% | Avg: $-41.72M Low: $-41.72M High: $-41.72M avg. -324.18% |
EPS
% change YoY
| $0.02 N/A | -$0.06 -335.26% | -$0.04 21.16% | Avg: -$0.03 Low: -$0.06 High: -$0.01 avg. 36.08% | Avg: -$0.04 Low: -$0.06 High: -$0.02 avg. -51.64% | Avg: -$0.07 Low: -$0.07 High: -$0.07 avg. -63.72% | Avg: -$0.03 Low: -$0.03 High: -$0.03 avg. 55.55% |
Operating Expenses
% change YoY
| $39.49M N/A | $44.50M 12.69% | $35.84M -19.46% | Avg: $-152.59M Low: $-152.59M High: $-152.59M avg. -525.74% | Avg: $-214.43M Low: $-214.43M High: $-214.43M avg. -40.52% | Avg: $-235.22M Low: $-235.22M High: $-235.22M avg. -9.69% | Avg: $-997.79M Low: $-997.79M High: $-997.79M avg. -324.18% |
FAQ
What is Mereo BioPharma Group stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -5.59% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -36.74M, average is -25.80M and high is -5.34M.
What is Mereo BioPharma Group stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 99.79% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $12.47M, average is $12.47M and high is $12.47M.
What is Mereo BioPharma Group stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -5.93% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$0.06, average is -$0.03 and high is $-0.00.
What is the best performing analyst?
In the last twelve months analysts have been covering Mereo BioPharma Group stock. The most successful analyst is Joseph Schwartz.